Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Stomach Neoplasms 1Neurofibromatosis 1 1Neurofibroma, Plexiform 1Neoplasms 1Keratosis, Actinic 1Heart Failure 1Gastrointestinal Neoplasms 1Disease 1Colorectal Neoplasms 1Breast Neoplasms 1Biliary Tract Neoplasms 1Arrhythmias, Cardiac 1

Interventions

obinutuzumab 1acalabrutinib 1Rituximab 1Population Groups 1Lenalidomide 1Control Groups 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Heart Failure × Control Groups × Clear all
NCT06092606 2023-10-23

A Multicenter Clinical Trial on DH001 Tablets in the Prevention of Doxorubicin-induced Cardiotoxicity in Cancer Patients

Monyan Pharmaceutical (Shanghai) Co., Ltd.

Phase 2 Unknown
90 enrolled

Arrhythmias, Cardiac, Heart Failure, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡